Corcept Therapeutics Inc.
Corcept Therapeutics Inc. price
About Corcept Therapeutics Inc.
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
- Stock ticker
- CORT
- Company
- Corcept Therapeutics Incorporated
- Industry
- Healthcare
- Category
- US
- Stock split / reverse split
- --
- Launch date
- Apr 14, 2004
- Listed exchange
- NASDAQ
Financials
Summary: CORT reported Revenue of 256.15M (+31.74%), beating expectations; EPS of 0.36 (+24.14%), beating expectations.
Corcept Therapeutics Inc. conversion tables
 |  |
|---|---|
| 0.5 CORT | 58.14 USD |
| 1 CORT | 116.28 USD |
| 5 CORT | 581.4 USD |
| 10 CORT | 1,162.8 USD |
| |
|---|---|
| 0.5 USD | 0.0043 CORT |
| 1 USD | 0.0085999 CORT |
| 5 USD | 0.043 CORT |
| 10 USD | 0.085999 CORT |
More to explore
FAQ
CORT is trading at $116.28, +0.04% over the last 24 hours. Track live moves on the price chart at the top of this page.
The CORT stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. CORT is currently trading at $116.28, +0.04% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on CORT price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. CORT's P/E ratio is currently 276.74 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from CORT; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against CORT's historical range and other companies in the Healthcare sector.
Corcept Therapeutics Incorporated's market cap is currently 12.56B USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.